Your browser doesn't support javascript.
loading
Gadolinium Enhanced T2 FLAIR is an Imaging Biomarker of Radiation Necrosis and Tumor Progression in Patients with Brain Metastases.
Heyn, Chris; Bishop, Jonathan; Moody, Alan R; Kang, Tony; Wong, Erin; Howard, Peter; Maralani, Pejman; Symons, Sean; MacIntosh, Bradley J; Keith, Julia; Lim-Fat, Mary Jane; Perry, James; Myrehaug, Sten; Detsky, Jay; Tseng, Chia-Lin; Chen, Hanbo; Sahgal, Arjun; Soliman, Hany.
Afiliación
  • Heyn C; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Bishop J; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Moody AR; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Kang T; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Wong E; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Howard P; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Maralani P; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Symons S; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • MacIntosh BJ; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Keith J; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Lim-Fat MJ; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Perry J; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Myrehaug S; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Detsky J; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Tseng CL; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Chen H; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Sahgal A; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
  • Soliman H; From the Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (C.H., J.B., A.R.M., T.K., E.W., P.H., P.M., S.S.), Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (C.H., A.R.M., T.K., E.W., P.H., P.M., S.S.), Sunnybrook Research Ins
Article en En | MEDLINE | ID: mdl-39107039
ABSTRACT
BACKGROUND AND

PURPOSE:

Differentiating radiation necrosis (RN) from tumor progression (TP) after radiotherapy for brain metastases is an important clinical problem requiring advanced imaging techniques which may not be widely available and are challenging to perform at multiple time points. The ability to leverage conventional MRI for this problem, could have meaningful clinical impact. The purpose of this study was to explore contrast enhanced T2 FLAIR (T2FLAIRc) as a new imaging biomarker of RN and TP. MATERIALS AND

METHODS:

This single-institution retrospective study included patients with treated brain metastases undergoing DSC-MRI between January 2021 and June 2023. Reference standard assessment was based on histopathology or serial follow-up including results of DSC-MRI for a minimum of 6 months from the first DSC-MRI. The index test was implemented as part of the institutional brain tumor MRI protocol and preceded the first DSC-MRI. T2FLAIRc and gadolinium enhanced T1 MPRAGE (T1c) signal were normalized against normal brain parenchyma and expressed as z-score. Mean signal intensity of enhancing disease for RN and TP groups were compared using unpaired t-test. Receiver operator characteristic (ROC) curves and area under the ROC curve (AUC) were derived by bootstrapping. DeLong test was used to compare AUC.

RESULTS:

56 participants (mean age, 62 years +/-12.7 [SD]; 39 females); 28 RN, 28 TP were evaluated. The index MRI was performed on average 73 days +/-34 [SD] before the first DSC-MRI. Significantly higher z-scores were found for RN using T2FLAIRc (8.3 versus 5.8, p<0.001) and T1c (4.1 versus 3.5, p=0.02). AUC for T2FLAIRc (0.83, 95% CI, 0.72-0.92) was greater than T1c (0.70, 95% CI, 0.560.83) (p = 0.04). The AUC of DSC derived rCBV (0.82, 95% CI, 0.70-0.93) was not significantly different from T2FLAIRc (p = 0.9).

CONCLUSIONS:

A higher normalized T1c and T2FLAIRc signal intensity was found for RN. In a univariable test, mean T2FLAIRc signal intensity of enhancing voxels showed good discrimination performance for distinguishing RN from TP. The results of this work demonstrate the potential of T2FLAIRc as an imaging biomarker in the work-up of RN in patients with brain metastases. ABBREVIATIONS AUC = area under the receiver operating characteristic curve; RN = radiation necrosis; ROC = receiver operating characteristic; SRS = stereotactic radiosurgery; T1c = contrast enhanced T1; T2FLAIRc = contrast enhanced T2 FLAIR; TP = tumor progression.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: AJNR Am J Neuroradiol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: AJNR Am J Neuroradiol Año: 2024 Tipo del documento: Article